Wedbush Boosts Earnings Estimates for Dianthus Therapeutics

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) – Stock analysts at Wedbush boosted their Q2 2025 earnings per share estimates for shares of Dianthus Therapeutics in a research note issued to investors on Tuesday, May 13th. Wedbush analyst L. Chico now expects that the company will post earnings per share of ($0.77) for the quarter, up from their prior forecast of ($0.79). Wedbush currently has a “Outperform” rating and a $36.00 target price on the stock. The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($2.61) per share. Wedbush also issued estimates for Dianthus Therapeutics’ Q3 2025 earnings at ($0.81) EPS, Q4 2025 earnings at ($0.84) EPS, FY2025 earnings at ($3.25) EPS, Q1 2026 earnings at ($0.74) EPS, Q2 2026 earnings at ($0.75) EPS, Q3 2026 earnings at ($0.76) EPS, Q4 2026 earnings at ($0.76) EPS, FY2026 earnings at ($3.01) EPS, FY2027 earnings at ($3.09) EPS, FY2028 earnings at ($2.61) EPS and FY2029 earnings at $1.70 EPS.

A number of other research analysts have also issued reports on DNTH. Guggenheim restated a “buy” rating and set a $84.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Robert W. Baird reduced their price objective on Dianthus Therapeutics from $58.00 to $50.00 and set an “outperform” rating for the company in a research report on Tuesday. Finally, HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research report on Tuesday. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $53.00.

Dianthus Therapeutics Stock Down 0.8%

Shares of NASDAQ DNTH opened at $18.75 on Thursday. Dianthus Therapeutics has a 52-week low of $13.37 and a 52-week high of $32.27. The stock has a market capitalization of $602.36 million, a P/E ratio of -7.50 and a beta of 1.48. The stock’s 50 day moving average price is $19.47 and its two-hundred day moving average price is $22.21.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Monday, May 12th. The company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($0.86) by $0.04. The company had revenue of $1.16 million during the quarter, compared to the consensus estimate of $0.81 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of hedge funds have recently bought and sold shares of DNTH. R Squared Ltd bought a new position in Dianthus Therapeutics during the fourth quarter worth $26,000. US Bancorp DE grew its position in Dianthus Therapeutics by 2,013.3% in the 1st quarter. US Bancorp DE now owns 1,585 shares of the company’s stock worth $29,000 after purchasing an additional 1,510 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of Dianthus Therapeutics during the 4th quarter worth about $33,000. KBC Group NV acquired a new position in shares of Dianthus Therapeutics during the fourth quarter valued at about $35,000. Finally, BNP Paribas Financial Markets bought a new stake in shares of Dianthus Therapeutics in the fourth quarter valued at about $59,000. 47.53% of the stock is currently owned by institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.